Lefluonia

Leflunomide, the active ingredient in Lefluonia, is an immunomodulator presented as a tablet for oral use. It treats rheumatoid arthritis and psoriatic arthritis in adult patients, helping to reduce joint inflammation and slow disease progression.

GNH USA supplies Lefluonia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is used in autoimmune inflammatory diseases that affect the joints and skin.

Rheumatoid arthritis: reduces joint pain, swelling and slows structural damage. Psoriatic arthritis: improves skin lesions and joint symptoms.

Leflunomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Headache: transient cranial discomfort. - Hypertension: elevated blood pressure readings. - Alopecia: thinning or loss of hair. - Elevated liver enzymes: mild increase in hepatic transaminases.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure. - Bone marrow suppression: anemia, leukopenia, or thrombocytopenia. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Stevens‑Johnson syndrome: severe skin reactions. - Life‑threatening infections: opportunistic infections due to immunosuppression. - Severe hypertension: hypertensive crisis requiring urgent care.

Before initiating therapy, several safety considerations should be addressed.

Pregnancy: contraindicated (Category X) – avoid use in pregnant women. Liver function: obtain baseline liver tests and monitor periodically. Hematology: perform complete blood counts before and during treatment. Blood pressure: monitor regularly, especially in patients with pre‑existing hypertension. Renal impairment: adjust use in severe renal dysfunction. Store below 25°C: keep in the original pack, protect from moisture.

Leflunomide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Methotrexate: additive hepatotoxicity and bone‑marrow suppression. - Strong CYP1A2 inhibitors (e.g., fluconazole): raise leflunomide levels. - Live vaccines: heightened risk of infection. - Cholesterol‑sequestering resins (e.g., cholestyramine): reduce leflunomide absorption.

Moderate Interactions (Monitor Closely):\n- NSAIDs: potential for increased liver enzyme elevation. - Statins: risk of myopathy may be enhanced. - ACE inhibitors or ARBs: possible additive blood‑pressure effects. - Oral contraceptives: may reduce contraceptive efficacy.